Companies › Cho Pharma
2 active drug programs in 2 registered trials: 2 Phase 1; Vaccines, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CHO-H01 Anti-CD20 monoclonal antibody | CD20 | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| CHO-V08 Glycoconjugate bivalent vaccine against Klebsiella pneumoniae K1 and K2 serotypes | – | Phase 1 | Klebsiella Pneumoniae Infection | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05950165 | CHO-H01 | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Dec 2026 |
| NCT07016152 | CHO-V08 | Phase 1 | Klebsiella Pneumoniae Infection | Vaccines | Apr 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.